Cytokinetics (NASDAQ: CYTK) Just Broke Out to a 52-Week High and Looks Headed Even Higher
The combination of a landmark Phase 3 trial success, accelerating U.S. and European commercial launches, and a fresh technical breakout makes this stock one of the more…
Written byGreg PatrickSource: Trades Of The Day
The combination of a landmark Phase 3 trial success, accelerating U.S. and European commercial launches, and a fresh technical breakout makes this stock one of the more interesting setups on the board. Our trade idea is targeting a 20%-36% potential return in the next 3-6 months.